1701053i cpr17 figures slides ppt - cancer progress report · 2020. 9. 18. · soft tissue sarcomas...

18

Upload: others

Post on 01-Mar-2021

2 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 2: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 3: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 4: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 5: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 6: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 7: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 8: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 9: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 10: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 11: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 12: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 13: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 14: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 15: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 16: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 17: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

Page 18: 1701053I CPR17 figures Slides PPT - Cancer Progress Report · 2020. 9. 18. · soft tissue sarcomas correlate with poor survival 2010 Phase trial of olaratumab insolidtumors Olaratumab

SUMMARY OF PRODUCT CHARACTERISTICS …...One mL of concentrate for solution for infusion contains 10 mg of olaratumab. Each 19 mL vial contains 190 mg of olaratumab. Each 50 mL vial

Welcome [canttboardjabalpur.org.in]canttboardjabalpur.org.in/english/downloads/cpr17.pdf · Gazette of EXTRAORDINARY 4 PART Il—section 4 PUBLISHED BY AUTHORITY REGD. NO. D. L-33004/99

ALLEGATO I RIASSUNTO DELLE CARATTERISTICHE DEL … · La terapia con olaratumab deve essere iniziata e condotta sotto la supervisione di medici esperti in ... In uno studio specifico

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI nu … · resuscitare (vezi pct. 4.4) . Doze . Doza recomandată de olaratumab este de 15 mg/kg administrată în perfuzie intravenoasă

ANHANG I ZUSAMMENFASSUNG DER MERKMALE DES … · Induktion dieser Enzyme durch eine Begleittherapie die Pharmakokinetik von Olaratumab beeinflusst. Im Gegenzug wird auch von Olaratumab

1701053I CPR17 Tables Slides PPT - Cancer Progress … types of leukemia ... Colectomy, hysterectomy, and salpingo-oophorectomy Thyroidectomy ... 1701053I_CPR17_Tables_Slides_PPT

Olaratumab imc 3 g3 ottobre 2010

1701053I CPR17 figures Slides PPT - Cancer Progress …cancerprogressreport.org/.../1701053I_CPR17_Figures_Slides_PDF.pdf · Figure 3 Púnts "owl with Precision Medicine to the Mid

DEPARTMENT OF HEALTH 1lr~~~4W¥JJ¥0:i: DRUG ......any case of adverse drug reaction related to olaratumab. As further assessment of the study results is As further assessment of the

1701053I CPR17 Tables Slides PPT - cancerprogressreport.org · Retinoblastoma predisposition syndrome Inherited bone marrow failure syndromes, such as Fanconi's anemia and telomere

1701053I CPR17 Tables Slides PPT - Cancer Progress Report

LARTRUVO™ (olaratumab) in Advanced Soft Tissue …€¦ · (olaratumab) in Advanced Soft Tissue Sarcoma Eli Lilly and Company Pediatric ODAC Meeting 22 June 2017 AVAILABLE FOR PUBLIC

INFORME SEOM DE EVALUACIÓN DE FÁRMACOS Informe · PDF fileINFORME SEOM DE EVALUACIÓN DE FÁRMACOS Informe de Evaluación SEOM de Olaratumab (Lartruvo®) en combinación con doxorrubicina

US FDA Update: Recent Trends in the Regulation of ...€¦ · Darzalex (daratumumab), Tecentriq (atezolizumab), Lartruvo (olaratumab), Bavencio (avelumab) 20 Expedited Development-

Olaratumab Exerts Antitumor Activity in Preclinical Models ... · malignant rhabdoid tumor, and this activity was enhanced by combination with either doxorubicin or cisplatin. Conclusions: